参考文献/References:
［1］王晓秋，李大金．卵巢功能早衰的免疫学发病机制及免疫治疗的研究进展 ［J］．国际妇产科学杂志，2016，43（3）：245-249．
［2］汪希鹏．卵巢恶性肿瘤的诊治进展和争议问题 ［J］．实用肿瘤杂志，2016，31（6）：499-501．
［3］张婷，贺婉红，俸灵林．化疗药物卵巢毒性的研究进展 ［J］．中国药理学与毒理学杂志，2016，30（8）：879-885．
［4］吕文漪，董晓英．卵泡发育与卵巢早衰相关性的研究进展 ［J］．医学研究杂志，2016，45（12）：160-162．
［5］MUNHOZ R R, PEREIRA A A, SASSE A D, et al Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis ［J］ JAMA oncology, 2016, 2(1): 65-73
［6］GAMZE B, NazlA, FILIZ S, et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro ［J］. Hyperfine Interactions, 2015, 30(12): 2912-2925.
［7］祝洪澜，崔恒．卵巢恶性肿瘤保留生育功能后化疗的策略及卵巢保护 ［J］．实用妇产科杂志，2016，32（11）：807-809．
［8］张春梅，李静，吕娟，等．促性腺激素释放激素类似物对卵巢肿瘤化疗患者卵巢功能的保护作用 ［J］．中国药物与临床，2016，16（9）：1300-1302．
［9］曾玉翠，吴瑞芳．卵巢组织冻存方案的优化研究进展 ［J］．国际生殖健康/计划生育杂志，2015，34（2）：141-144．
［10］El-Agwany A M S.Peritoneal carcinomatosis index in advanced ovarian malignancy either by multislice CT verus laparotomy:a comparative study ［J］. Indian Journal of Gynecologic Oncology, 2015, 13(1): 1-8.
［11］YOSHIDA A, DERCHAIN S F, PITTA D R, et al. Comparing the Copenhagen index (CPH-I) and risk of ovarian malignancy algorithm (ROMA): two equivalent ways to differentiate malignant from benign ovarian tumors before surgery? ［J］. Gynecologic Oncology, 2016, 140(3): 481-485.
［12］FUJIWARA H, SUZUKI M, TAKESHIMA N, et al. Evaluation of human epididymis protein 4 (HE4) and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women ［J］. Tumour Biology:the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, 36(2): 1045-1053.
［13］HORICKS F, STEEN G D, HOUBEN S, et al. Folliculogenesis is not fully inhibited during GnRH analogues treatment in mice challenging their efficiency to preserve the ovarian reserve during chemotherapy in this model［J］. PLOS One, 2015, 10(9): e0137164. ［14］DEL MASTRO L, LAMBERTINI M. Temporary ovarian suppression with Gonadotropin-Releasing hormone agonist during chemotherapy for fertility preservation: toward the end of the debate? ［J］. The Oncologist, 2015, 20(11): 1233-1235.
［15］狄文，宋柯琦．化疗对年轻恶性肿瘤患者卵巢功能的影响 ［J］．中国实用妇科与产科杂志，2016，32（9）：908-910．
［16］祝洪澜，李小平，王朝华，等．GnRHa在非良性卵巢肿瘤保留生育功能患者中的应用 ［J］．实用妇产科杂志，2014，30（4）：278-281．
［17］崔恒，程洪艳，鹿群．肿瘤生殖学及宫颈癌治疗中生理和生育功能保护问题 ［J］．中华妇幼临床医学杂志(电子版)，2015，11（4）：429-432．
［18］ZHANG Ling, CAO Xili, ZHANG Liqian, et al. UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy ［J］. Cancer Chemotherapy and Pharmacology, 2016, 77(3): 629-634.
［19］SU H C, HAUNSCHILD C, CHUNG K, et al. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients ［J］. Cancer, 2014, 120(23): 3691-3698.
［20］ELGINDY E, SIBAI H, ABDELGHANI A, et al. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis ［J］. Obstetrics and Gynecology, 2015, 126(1): 187-195.